It should also be noted that pralsetinib was subsequently approved for RET fusions in advanced NSCLC in September 2020 and advanced, mutated or fusion-positive thyroid cancer patients (similar to the selpercatinib indication) in December 2020 based upon the ARROW trial. Here, RET is linked to thyroid gland carcinoma.